​

Gilead Sciences (GILD) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

GILD Stock Forecast

Gilead Sciences (GILD) stock forecast, based on 56 Wall Street analysts, predicts a 12-month average price target of $109.43, with a high of $132.00 and a low of $83.00. This represents a 3.55% increase from the last price of $105.68.

$60 $75 $90 $105 $120 $135 High: $132 Avg: $109.43 Low: $83 Last Closed Price: $105.68

GILD Stock Rating

Gilead Sciences stock's rating consensus is Buy, based on 56 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 32 Buy (57.14%), 23 Hold (41.07%), 1 Sell (1.79%), and 0 Strong Sell (0.00%).

Buy
Total 56 1 23 32 Strong Sell Sell Hold Buy Strong Buy

GILD Price Target Upside V Benchmarks

TypeNameUpside
StockGilead Sciences3.55%
SectorHealthcare Stocks 33.91%
IndustryDrug Manufacturers - General Stocks37.84%

Price Target Trends

1M3M12M
# Anlaysts-322
Avg Price Target-$129.33$90.95
Last Closing Price$105.68$105.68$105.68
Upside/Downside-22.38%-13.94%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Apr, 2541511--30
Mar, 2551511--31
Feb, 2541211--27
Jan, 2541312--29
Dec, 2451413--32
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Mar 11, 2025Terence FlynnMorgan Stanley$130.00$114.4313.61%23.01%
Mar 05, 2025Johnson Rice$126.00$115.449.15%19.23%
Jan 07, 2025Brian AbrahamsRBC Capital$83.00$90.63-8.42%-21.46%
Nov 07, 2024Joseph CatanzaroPiper Sandler$105.00$90.0916.55%-0.64%
Oct 21, 2024Evan David SeigermanBMO Capital$94.00$86.119.16%-11.05%
Oct 21, 2024Andrew BerensLeerink Partners$96.00$86.7210.70%-9.16%
Oct 18, 2024Terence FlynnMorgan Stanley$84.00$87.07-3.53%-20.51%
Sep 23, 2024Michael YeeJefferies$95.00$83.7613.42%-10.11%
Sep 12, 2024Salveen RichterGoldman Sachs$71.00$82.85-14.30%-32.82%
Sep 12, 2024Terence FlynnMorgan Stanley$79.00$82.63-4.39%-25.25%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Mar 26, 2025CitigroupBuyBuyhold
Mar 11, 2025Morgan StanleyOverweightOverweighthold
Mar 04, 2025OppenheimerOutperformOutperformhold
Feb 18, 2025Deutsche BankBuyupgrade
Jan 10, 2025Morgan StanleyReduceOverweightupgrade
Jan 07, 2025RBC CapitalSector PerformSector Performhold
Nov 13, 2024CitigroupBuyinitialise
Oct 21, 2024BernsteinOutperformOutperformhold
Oct 21, 2024RBC CapitalUnderperformUnderperformhold
Oct 21, 2024Leerink PartnersOutperformupgrade

Financial Forecast

EPS Forecast

$0 $2 $4 $6 $8 $10 $11 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$0.07$4.96$3.66$4.54$0.38----
Avg Forecast$6.95$8.20$7.10$6.75$4.38$7.59$7.95$8.47$9.07
High Forecast$7.22$8.53$7.42$7.05$4.72$8.42$9.84$10.05$9.61
Low Forecast$6.74$7.96$6.84$6.58$3.87$6.40$5.77$5.94$8.66
Surprise %-98.99%-39.51%-48.45%-32.74%-91.32%----

Revenue Forecast

$24B $26B $28B $30B $32B $34B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$24.69B$27.30B$27.28B$27.12B$28.75B----
Avg Forecast$24.37B$26.67B$26.53B$27.10B$28.32B$28.49B$29.34B$30.74B$32.22B
High Forecast$25.12B$27.48B$27.44B$27.28B$28.60B$29.85B$29.36B$30.85B$33.68B
Low Forecast$23.80B$26.05B$25.78B$26.91B$28.10B$27.87B$29.31B$30.63B$31.10B
Surprise %1.30%2.38%2.84%0.06%1.54%----

Net Income Forecast

$-5B $-1B $3B $7B $11B $15B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$89.00M$6.22B$4.59B$5.67B$480.00M----
Avg Forecast$-826.75M$5.09B$3.23B$5.67B$5.40B$9.33B$7.55B$8.20B$11.41B
High Forecast$656.68M$6.10B$3.88B$6.80B$5.94B$10.60B$12.37B$12.64B$12.09B
Low Forecast$-2.31B$4.07B$2.58B$4.53B$4.87B$8.06B$7.26B$7.47B$10.90B
Surprise %-110.77%22.36%42.16%--91.12%----

GILD Forecast FAQ

Is Gilead Sciences stock a buy?

Gilead Sciences stock has a consensus rating of Buy, based on 56 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 32 Buy, 23 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Gilead Sciences is a favorable investment for most analysts.

What is Gilead Sciences's price target?

Gilead Sciences's price target, set by 56 Wall Street analysts, averages $109.43 over the next 12 months. The price target range spans from $83 at the low end to $132 at the high end, suggesting a potential 3.55% change from the previous closing price of $105.68.

How does Gilead Sciences stock forecast compare to its benchmarks?

Gilead Sciences's stock forecast shows a 3.55% upside, underperforming the average forecast for the healthcare stocks sector (33.91%) and underperforming the drug manufacturers - general stocks industry (37.84%).

What is the breakdown of analyst ratings for Gilead Sciences over the past three months?

  • April 2025: 13.33% Strong Buy, 50.00% Buy, 36.67% Hold, 0% Sell, 0% Strong Sell.
  • March 2025: 16.13% Strong Buy, 48.39% Buy, 35.48% Hold, 0% Sell, 0% Strong Sell.
  • February 2025: 14.81% Strong Buy, 44.44% Buy, 40.74% Hold, 0% Sell, 0% Strong Sell.

What is Gilead Sciences’s EPS forecast?

Gilead Sciences's average annual EPS forecast for its fiscal year ending in December 2025 is $7.59, marking a 1897.37% increase from the reported $0.38 in 2024. Estimates for the following years are $7.95 in 2026, $8.47 in 2027, and $9.07 in 2028.

What is Gilead Sciences’s revenue forecast?

Gilead Sciences's average annual revenue forecast for its fiscal year ending in December 2025 is $28.49B, reflecting a -0.91% decrease from the reported $28.75B in 2024. The forecast for 2026 is $29.34B, followed by $30.74B for 2027, and $32.22B for 2028.

What is Gilead Sciences’s net income forecast?

Gilead Sciences's net income forecast for the fiscal year ending in December 2025 stands at $9.33B, representing an 1842.97% increase from the reported $480M in 2024. Projections indicate $7.55B in 2026, $8.2B in 2027, and $11.41B in 2028.